If you didn’t have time Wednesday, I urge you to read this now . . . the story of a long-time, high-ranking REPUBLICAN Congressional staffer, who levels a devastating indictment: Goodbye to All That: Reflections of a GOP Operative Who Left the Cult.
MY FRIEND PATTY HAS WRITTEN A NEW LITTLE NOVEL
And they made a charming little movie to promote it. Three minutes.
STARTING A NEW BUSINESS – II
And now WickedStart is the subject of a New York Times follow-up. (Reminder: I have a sliver of this. But since it’s free, and the Times seems to think it’s useful, I don’t feel too guilty plugging it.)
ARE YOU THESE TWO THINGS?
1. A fantasy football or fantasy baseball enthusiast?
2. Rich? (Rich-ish?)
Just in case you are, could you Me-Mail me?
DVAX / TTNP UPDATE
Guru: “It’s amazing how much better mousetraps DVAX (and TTNP) really are. Market just doesn’t care. The market WILL care when TTNP is sold (highly probable, though no guarantee) and when DVAX is launched (next year). DVAX has data to be released September 17 at the ICAAC meeting and then in October, highly likely that the CDC will recommend universal hep B vaccine for diabetics and DVAX is the hands down winner over the existing vaccine. Not in any way equivocal. This vaccine truly is the better mousetrap!”
Guru: “They are presenting data on osteoarthritis trial September 17. Title of talk suggests they saw significant improvement in pain and function and increase in cartilage. Provides support for osteoporosis trial. That trial’s last patient was done in late June or early July. Thus it is likely Novartis has at least a preliminary idea of the results. I’m hearing the official final data will be out in November. Always a lot of uncertainty in biotech but I remain positive.”
Guru: “DNDN had a conference call today. August sales were $22 million up from $19 million in July. Average reimbursement time is 30 days. One doc was reimbursed in 8 days. Issue is not price or patients with the right diagnosis: it is only reimbursement. As soon as each doc sees he is getting timely reimbursement he has lots of patients to put on. They have reduced head count by 25 percent. They are break-even at $500 million a year and they have enough cash to get there. Bottom line: worst is behind them stock is going up.”
Quote of the Day
Life is too short to be small.~Disraeli
Request email delivery
- Sep 17:
Better Than Recycling
- Sep 15:
Tony Blair On Brexit
- Sep 13:
Patience, Jackass, Patience
- Sep 12:
A Word To White Supremacists
- Sep 11:
Have You Actually LISTENED To Ilhan Omar?
- Sep 10:
History’s Not Kind To The Guys Who Held Mussolini’s Jacket
- Sep 8:
Vast Masses Of Filth
- Sep 6:
The Roots Of All Evil — And One Good Solution
- Sep 5:
How Labor Unions Should Move Forward
- Sep 4:
- Sep 17: